Antigen-presenting molecules that serve as ligands for checkpoint receptors–essential context for LAG-3 biology.
MHC class II molecules (HLA-DR, -DP, -DQ in humans) are expressed on professional antigen-presenting cells where they present extracellular-derived peptides to CD4+ helper T cells. This initiates adaptive immune responses against pathogens and tumors.
MHC II expression is generally limited to APCs, but inflammation and certain tumor types can induce aberrant expression on other cell types, including tumor cells themselves.
What MHC-II Does: MHC class II molecules present protein fragments to CD4+ "helper" T cells. They're normally expressed on professional immune cells like dendritic cells, macrophages, and B cells.
In Tumors: Some tumors express MHC-II, which can either stimulate immunity (by presenting antigens) or suppress it (by engaging LAG-3).
Beyond antigen presentation, MHC II serves as the primary ligand for LAG-3Loading.... LAG-3 binds MHC II with higher affinity than CD4, and this binding delivers inhibitory signals to the T cell.
This creates a paradox: MHC II expression can either activate T cells (through antigen presentation) or suppress them (through LAG-3 engagement). The outcome depends on the balance of co-stimulatory and co-inhibitory signals in each interaction.
The LAG-3 Connection: MHC-II is the primary ligand for LAG-3. When LAG-3 on a T cell binds MHC-II, it delivers a suppressive signal.
Therapeutic Implication: Anti-LAG-3 drugs aim to block this interaction to release T cells from suppression.
Understanding whether MHC II expression promotes or suppresses immunity requires knowing whether LAG-3 engagement is occurring. Expression alone cannot distinguish between activating and suppressive contexts.
iFRETLoading... measurement of LAG-3/MHC II interaction provides this functional context–revealing whether MHC II-expressing cells are actively engaging LAG-3 checkpoint suppression.
Expression vs Engagement: High MHC-II expression doesn't mean LAG-3 is being engaged. Like PD-L1, actual molecular engagement provides different information than expression.
FRET Opportunity: Measuring LAG-3/MHC-II engagement could improve patient selection for anti-LAG-3 therapy.
